Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MK-1484 alone and with pembrolizumab in advanced or metastatic solid tumors
NL-OMON51516Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-1484 in Nonhematologic neoplasms (2 arms), sponsored by Merck & Co. Primary endpoints: Occurrence of dose-limiting toxicity, Adverse events and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
MK-1484
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON51516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51516.